Staphylococcus aureus Mortality: U.S. Data & Context
CDC estimates ~19,000 U.S. deaths annually are attributable to Staphylococcus aureus infections (invasive MRSA + MSSA). This is likely an underestimate due to:
- Attribution difficulty (comorbidities, polymicrobial infections)
- Outpatient/non-invasive cases not captured
- Surveillance gaps (not all states report uniformly)
- Post-discharge mortality not fully tracked
Key Epidemiology
- MRSA: ~80,000 invasive infections/year; ~11,000 deaths. Community-associated (CA-MRSA) now > healthcare-associated (HA-MRSA).
- MSSA: More common; similar mortality per case.
- High-risk groups: >65 yrs, hemodialysis, ICU, surgery, indwelling devices, immunosuppression, PWID.
- Infection types: Bacteremia, endocarditis, osteoarticular, pneumonia, SSTI (skin/soft tissue).
Prevention & Control
- Hand hygiene, contact precautions, chlorhexidine bathing (ICU).
- Decolonization (intranasal mupirocin + CHG wash) pre-op, ICU, recurrent SSTI.
- Antimicrobial stewardship (reduce selection pressure).
- Vaccine candidates in trials (none licensed).
- Surveillance: NHSN, EIP/ABCs.
Clinical Pearl
Any S. aureus bacteremia requires echocardiography (TTE → TEE if negative/high risk) for endocarditis, source control (remove lines, drain abscess), and 2–6 weeks IV antibiotics (β-lactam for MSSA; vancomycin/daptomycin/ceftaroline for MRSA).
Public Health - Related Articles
- Comprehensive Health & Safety Audit Checklist for Businesses
- Black Mold Detection: Signs, Risks & Prevention
- Unlock the Benefits of Nose Breathing: A Simple Guide
- Sustainable Winter Living: Eco-Friendly Practices for a Greener Season
- Understanding the Repertory Grid: A Tool for Personal Construct Theory
- Understanding Self-Help Organizations: Support & Community
- Safe Hand Tool Handling: Preventing Injuries at Home
